Closures for pharmaceutical containers

By designing a removable closure cap, using snap fit connections and elastic seals, the disassembly problem of the pharmaceutical container seal in the closure integrity test is solved, improving the ease of operation and the life of the seal, while reducing costs.

CN114258377BInactive Publication Date: 2024-11-08SANOFI SA(FR)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080057985.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-08-21
Filing Date
2020-08-17
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The seals of existing pharmaceutical containers are difficult to disassemble during seal integrity testing and leakage testing, and the traditional sealing caps are complex in operation, easy to damage the container, and cost high.

Method used

A closed cap is designed including a cap body and a fastening part, which consists of a retainer part and a fastening part, the fastening part has a fastener that is elastically and radially deformable, and the snap feature is releasably connected to the cylinder. The radially widened edges at the outlet end of the body provide snap fit connections for easy removal and reuse.

Benefits of technology

The removable elastic seal fixation of the pharmaceutical container is achieved, reducing operational complexity and risk of damage, improving seal life and reducing manufacturing costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114258377B_ABST
    Figure CN114258377B_ABST
Patent Text Reader

Abstract

The present disclosure relates to a closure cap for sealing an outlet end (7) of a barrel (2) of a medicine container (1), wherein the outlet end (7) has a radially widened edge (11), and the outlet end (7) can be sealed by an elastic seal (80), wherein the elastic seal (80) includes a flange portion (94), and the flange portion is configured to be adjacent to the outlet end (7) in the longitudinal direction. The closure cap (20) comprises: a cap body (22), which includes a retainer portion (24) and a fastening portion (26), wherein the retainer portion (24) is configured to be adjacent to the outlet end (7) in the longitudinal direction. The resilient seal (80) is engaged, wherein the fastening portion (26) includes a resiliently and radially deformable fastener (28), the fastener including a snap feature (30) configured to releasably engage with a radially widened edge (11) of the outlet end (7), and wherein the longitudinal distance (D) between the retainer portion (24) and the snap feature (30) is sized to receive the radially widened edge (11) and the flange portion (94) of the resilient seal (80) between the retainer portion (24) and the snap feature (30).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to the field of pharmaceutical containers such as bottles, cartridges, capsules or vials. Specifically, the present disclosure relates to a primary package configured to contain a liquid medicament. The primary package, such as a bottle, cartridge, vial or capsule, is usually filled with a liquid medicament, such as an injectable liquid medicament. Background Art

[0002] Pharmaceutical containers, such as bottles, cartridges, capsules or vials, include an outlet port that must be closed and sealed in a liquid-tight and / or airtight manner. Since the interior of the pharmaceutical container must be sterile, a seal is usually non-detachably fixed on or at the outlet port of the pharmaceutical container. The seal can be pierced by a piercing element such as a cannula or an injection needle so that a liquid can be drawn into or discharged from the interior of the pharmaceutical container and / or a liquid substance, such as a liquid medicament, can be drawn out or discharged from the interior of the pharmaceutical container.

[0003] The medicine container can be filled with a liquid, such as an injectable medicine. The medicine container can also hold a lyophilized medicine. Here, the seal can be penetrated by a certain type of application device so that a solvent or diluent is added to the interior of the medicine container to prepare or reconstitute a liquid medicine in the medicine container.

[0004] For the purpose of conducting a container closure integrity test, a specially prepared pharmaceutical container sealed by a commercially available seal may be provided. For the purpose of conducting a container closure integrity test and / or conducting a leak test, such as a helium leak test, a pharmaceutical container may be specially prepared. Here, the barrel of the pharmaceutical container may include a well-defined through opening, such as a laser drilled hole of relatively small size that defines a certain leak rate when the interior of the sealed container is subjected to a pressure different from the ambient pressure.

[0005] The barrel of the pharmaceutical container that is designed or prepared especially for the container closure integrity test is quite expensive.In addition, this barrel can be made of glassy material, i.e. fragile material, such as glass.The traditional closure cap for sealing the barrel outlet end usually comprises a crimped metal cap, which is crimped to the barrel outlet end by a specific tool so that the seal is fixed to the outlet end.If the same test barrel is used together with a series of seals, it is quite troublesome for the operator to remove the crimped metal cover from the outlet end.In addition, this disassembly is usually accompanied by an increased risk of damaging the container barrel.

[0006] Therefore, it is desirable to provide an improved closure for a medicine container, wherein the closure is capable of removably securing an elastic seal to the outlet end of the barrel of the medicine container. The overall operation of the container closure should be simple and easy to operate. The assembly and disassembly of the closure should be intuitive and easy to understand. The closure should provide a durable and stable and leakproof attachment method and secure the elastic seal to the outlet end of the medicine container. In addition, the closure should be easy to manufacture and of moderate cost. Summary of the invention

[0007] On the one hand, a closure cap for sealing the medicine container barrel outlet end is provided.The outlet end of the barrel has a radially widened edge.The outlet end can be further sealed or sealed by an elastic seal.The elastic seal comprises a flange portion.The flange portion is configured to abut against the outlet end of the barrel in a longitudinal direction.Here, and in this context, the longitudinal direction can be consistent with the axial direction.The longitudinal direction and / or the axial direction can extend parallel to or overlap with the longitudinal center axis of, for example, a tubular barrel or a medicine container.

[0008] The closure cap comprises a cap body, the cap body comprises a retainer portion and a fastening portion, the retainer portion is configured to engage with the elastic seal, and the fastening portion is configured to engage with the radially widened edge of the outlet end.

[0009] The fastening portion includes an elastically and radially deformable fastener. The fastener includes a snap feature configured to releasably engage with a radially widened rim of the barrel outlet end.

[0010] In addition, the longitudinal distance or axial distance between the retainer portion and the snap feature is dimensioned to receive the radially widened rim of the outlet end and the flange portion of the elastic seal between the retainer portion and the snap feature. In this way, and by appropriately designing the distance between the retainer portion that can engage with the elastic seal and the snap feature that can engage with the outer side of the radially widened rim, a snap-fit ​​connection and / or positive fit can be provided between the closure cap and the barrel of the medicament container.

[0011] If the user applies the upper pulling force higher than the predetermined threshold force, the elastic and radially deformable fastener can well separate and release the snap feature from the radially widened edge. Like this, the closing cap provides the snap fit connection and the fixing based on the snap fit of the outlet end of the elastic seal to the medicine container barrel. This snap connection is particularly useful for the medicine container prepared for gas leak test (for example, in order to carry out the container closure integrity test). Because the snap feature of the fastening part is configured to releasably engage with the radially widened edge of the outlet end, the possibility and the danger of damaging the barrel when removing or separating the closing cap from the outlet end of the barrel are greatly reduced. Therefore, the total life of the barrel specially configured and prepared for the leak test purpose can be increased.

[0012] According to another example, the longitudinal distance between the retainer portion and the snap feature is less than or equal to the sum of the longitudinal extension of the radially widened edge of the outlet end and the longitudinal thickness of the flange portion of the elastic seal.When suitably assembled to the outlet end of the cylinder, the flange portion of the elastic seal is directly longitudinally or axially adjacent to the distal face of the cylinder.The distal face of the cylinder can contribute to the radially widened edge.The radially widened edge extends from the distal face to the proximal abutment face in the longitudinal direction, and the proximal abutment face overlaps with the stepped reduction portion of the radially widened edge.The proximal abutment face or the contact surface of the radially widened edge are configured to engage with the snap feature of the fastening portion.Typically, the snap feature of the fastening portion protrudes radially inwards, and is clamped below the abutment face or the contact surface at the proximal end of the radially widened edge.The radially widened edge is normally a radially outwardly protruding edge.

[0013] When the longitudinal distance between the retainer portion and the snap feature is less than the sum of the longitudinal extension of the radially widened rim and the longitudinal thickness of the flange portion, the snap-fit ​​engagement between the snap feature and the radially widened rim is obtained only by at least slight axial or longitudinal compression of the resilient seal. In this way, the sealing ability of the resilient seal and the container closure integrity can be increased. In this configuration, the seal is pre-tensioned and maintained in a pre-tensioned or pre-biased state, such as a slightly squeezed state on or at the outlet end of the barrel.

[0014] For other examples, where the longitudinal distance between the retainer portion and the snap feature is equal to or substantially equal to the sum of the longitudinal extension of the radially widened rim and the longitudinal thickness of the flange portion, at least a loose-free fixation and attachment of the elastic seal to the outlet end can be achieved.

[0015] According to another example, the cap body of the closure cap includes a cover and a sidewall. The cover and the sidewall form a cup-shaped receiving portion. The cup-shaped receiving portion is configured to receive the radially widened edge of the outlet end and the flange portion of the elastic seal. The size and configuration of the cup-shaped receiving portion are designed to receive the radially widened edge and the flange portion only when the elastic seal is attached to the outlet end, for example, when at least a portion of the elastic seal is located in the outlet end of the barrel.

[0016] The cover may include a closed cover. The cover may include a substantially flat or flat disc covering all or at least a portion of the outer surface of the seal. When properly assembled, the cover may include or may form an abutment surface facing the outer surface of the elastic seal and directly abutting the outer surface of the elastic seal. The cover may not have any through openings or depressions. The cover may be a closed cover. The cover is impenetrable for syringes or other puncture tools. The cover provides a relatively high anti-puncture mechanical resistance.

[0017] The sidewall may be cylindrical or tubular. The sidewall and the cover may be integrally formed. The sidewall may extend substantially parallel to the surface normal of at least the lower side of the cover. The sidewall may extend away from the cover in a direction substantially parallel to the surface normal of the adjacent face of the cover. The sidewall may not have any longitudinal slits or recesses. In this way, the sidewall has a relatively high mechanical stability and / or rigidity. The mutual connection of the sidewall and the cover provides mutual stabilization of the cover and the sidewall. In other words, the sidewall connected to the cover provides an increase in the reinforcement and rigidity of the cover. Placing the cover oppositely also enhances the rigidity and rigidity of the sidewall.

[0018] In some examples, the fastening portion is integrated into the side wall. In some examples, the fastening portion is formed or constituted by the side wall. In other words, the fastening portion and the side wall can coincide.

[0019] In addition, the cup-shaped receiving portion formed by the sidewall and the cover portion does not have any through opening or depression. Except the lower end of the sidewall relative to the cover portion, the cup-shaped receiving portion does not include any opening. In this way, and when suitably attached to the outlet end of the barrel, the closed cup-shaped receiving portion provides quite effective protection to the elastic seal, to resist environmental influences, such as electromagnetic radiation, humidity and / or particles, such as dust. Typically, the closure is opaque to electromagnetic radiation in at least one scope in the visible spectrum range, infrared spectrum range and ultraviolet spectrum range. In this way, the closure cap provides long-term protection for the elastic seal.

[0020] According to another example, the snap feature comprises a projection protruding from the inner surface of the sidewall. The projection of the snap feature may comprise at least one chamfered edge and / or an introduction ramp. This enables and facilitates a mechanical snap fit engagement with at least one of the flange portion of the elastic seal and the radially widened edge of the barrel outlet end. In the process of the closure cap being connected to the radially widened edge of the outlet end, the projection is used to bend or deform the fastener, thereby deforming the entire fastening portion, for example the entire sidewall radially outwards.

[0021] When the projection passes through the radially widened edge in the longitudinal direction, under the effect of the inherent elastic restoring force, the projection can be stuck in the recessed portion of the radially widened edge below. Typically, the projection comprises a chamfered edge at the distal end, i.e., facing the end of the retainer portion, and at the proximal end, i.e., away from the end of the retainer portion. The chamfered edge facing the proximal side, for example, is implemented as an introduction ramp, helps and / or supports the radial widening sidewall and / or radially outward movement of the fastening portion and the fastener in the process of pushing or pressing the closure cap to the outlet end in the proximal direction. The chamfered edge facing the distal side of the projection protruding radially inward effectively causes the radial widening and / or radially outward displacement or deformation of the fastening portion and / or the fastener in the process of disassembling the closure cap from the outlet end.

[0022] Typically, the distally facing chamfered edge is steeper than the proximally facing chamfered edge. In this way, the assembly force that may be required to connect the closure cap to the outlet end is less than the pull-off force required to separate the closure cap from the outlet end.

[0023] According to another example, the sidewall of the cap is tubular. In addition, the snap feature comprises an edge that radially projects inwards. Both the sidewall and the snap feature can be free of any recess, slit or through opening. In this way, a tensile and mechanically stable sidewall and / or corresponding snap feature can be provided. Even if the closure cap, which is usually made of a polymer or plastic material, creeps, a reliable and durable elastic seal can still be provided to prevent leakage.

[0024] According to another example, the longitudinal thickness of the cover at the radial center of the cover is greater than the longitudinal thickness of the cover at a certain radial distance from the radial center of the cover. In other words, the longitudinal thickness of the cover increases from the radially outward region to the radially central region. The longitudinal thickness of the cover can be increased continuously, gradually or in a discontinuous step-wise manner. Increasing the thickness of the cover at its radial center compared to the radially outer region is conducive to providing a well-defined elastic bending or elastic deformation of the cover in the process of pulling or disengaging the closure cap from the outlet end.

[0025] Typically, the sidewall is connected to the radially outward portion of the cover. In particular, the sidewall may abut the cover in the region where the cover has a minimum thickness. Such a geometrical realization of the cover may be particularly beneficial. In this way, the flexibility of the cover in the radially outer region is greater than the flexibility of the cover in the radially central region. This helps to lift or deform at least a portion of the cover during the process of pulling the closure cap off the outlet end.

[0026] During the process of disassembling or separating the closing cap from the outlet end, only certain circumferential portions of the sidewall and / or the snap-fit ​​feature can be disengaged from the radially widened rim. The deformation of the closing cap allows air to enter the space between the interior of the cup-shaped receiving portion and the exterior of the elastic seal and the radially widened rim. This may facilitate the continued separation of the closing cap from the radially widened rim.

[0027] According to another example, the snap feature is located at or near the free end of the fastening portion. The free end of the fastening portion faces away from the retainer portion. Typically, the snap feature is located inside the free end of the fastening portion. A second snap feature is located at the free end of the side wall, which faces away from the retainer portion. In this way, the snap feature is located at a portion or end of the fastening portion or side wall that exhibits the greatest flexibility because it includes the greatest distance to the retainer portion or cover portion, which inherently stabilizes the fastening portion or side wall.

[0028] According to another example, the snap feature includes an introduction ramp or chamfered edge to engage with at least one of the flange portion of the elastomeric seal and the radially widened rim of the outlet end. Typically, the introduction ramp faces in the proximal direction, thereby causing the snap feature and the radial widening or radially outward deformation of the fastener, the fastening portion and / or the sidewall during assembly of the closure cap to the outlet end of the barrel.

[0029] According to another example, the retainer part and the fastening part are formed in one piece. The cap body is made of polymeric material and / or the cap body is made of plastic material. Typically, the closing cap as a whole can be implemented as an injection-molded plastic part. The closing cap can include an integral cap body. The cap body can overlap with the closing cap and can constitute the closing cap. The barrel of the medicine container can include or can be made of a glassy material, such as glass. In some examples, the barrel of the medicine container is made of polymeric material and / or plastic material. The barrel of the container is usually transparent to electromagnetic radiation within at least one range in the visible spectrum range, the infrared spectrum range and the ultraviolet spectrum range.

[0030] According to another example, the closure cap comprises an outer flange portion protruding radially outwards from at least one of the retainer portion and the fastening portion. Typically, in some examples, the outer flange portion belongs to the cover portion. The retainer portion and the flange portion can constitute the cover portion. In this regard, the flange portion can include or can represent an extension extending radially outwards of the retainer portion. The upper portion of the outer flange portion or the outer surface facing the distal side can be flush with the upper outer surface of the retainer portion and / or the cover portion.

[0031] The outer flange portion may protrude radially outward from the outer side of the side wall, and thus radially outward from the outer side of the fastening portion of the cap body.

[0032] The flange portion extending radially outwards enables good gripping of the cap body, in particular for removing the closure cap from the outlet end.

[0033] According to another example, the outer flange portion comprises a lower gripping surface facing the fastening portion or facing the proximal longitudinal direction. The lower gripping surface can extend substantially parallel to the outer surface of the cap or the outer flange portion. The lower gripping surface can well define and intuitively grip the closure cap so that the closure cap can be easily and well pulled off from the outlet end of the barrel.

[0034] According to another example, the outer flange portion comprises an outer rim protruding from the lower gripping surface in the longitudinal direction. The outer rim may coincide with or be flush with the outer side edge of the flange portion. The outer rim may form a longitudinal extension of the circumferential side edge of the outer flange portion. Typically, the outer rim protrudes from the lower gripping surface of the outer flange portion in the proximal direction. The outer rim further stabilizes the outer flange portion. In addition, the outer rim provides a relatively non-slip and good grip for the fingers of the user who grip under the lower gripping surface in order to lift the closure.

[0035] In addition, according to another example, the outer flange portion includes a plurality of radially extending struts extending from the fastening portion to the outer edge. Typically, the radially extending struts extend radially outward from the fastening portion, for example, from the outer side of the closure cap sidewall to the outer edge. The radially extending struts further enhance the stability and / or rigidity of the outer flange portion. In addition, the radially extending struts help provide a non-slip grip of the lower gripping surface by the user's fingers.

[0036] According to another example, the fastening portion includes a tamper-evident seal. The tamper-evident seal includes a frangible area. The frangible area includes at least a first frangible section and a second frangible section. The first frangible section and the second frangible section are connected to each other by a frangible connector. The frangible connector may include a structural weakening or a perforation, so that there is a perforated connection between the first frangible section and the second frangible section. The tamper-evident seal may be formed integrally with the cap body, or may be integrated into the cap body. The tamper-evident seal irreversibly breaks or disintegrates when the closure is separated or removed from the barrel outlet end. In this way, and once the tamper-evident seal is broken, it is a clear indication to the user of the medication container that the medication container has been opened before.

[0037] Tamper evident closures are particularly useful for examples where the medication container is to be filled with medication. Since the removable closure cap allows the seal to be completely detached and removed from the outlet end, it is important to indicate that the closure cap that is actually assembled and attached to the outlet end of the barrel has previously been removed from the barrel. In this case, once the closure cap has been disassembled or removed from the outlet end, the medication container may no longer meet the predetermined clean or sterile conditions.

[0038] Typically, the tamper-evident seal may include an inner diameter adapted to fit the outer diameter of the stepped tapered neck of the barrel of the medicament container. In an unbroken and initial state, the inner diameter of the tamper-evident seal is smaller than the outer diameter of the radially widened rim of the barrel outlet end. Separating the closure cap from the outlet end of the barrel requires at least one of separation of the frangible region of the tamper-evident seal from the side wall of the closure cap and separation or breaking of the frangible connection between the frangible sections of the tamper-evident seal.

[0039] According to another aspect, the disclosure relates to a medicine container. The medicine container comprises a barrel, which comprises an outlet end. The outlet end of the barrel comprises a radially widened edge. The edge is a radially outwardly protruding edge, typically protruding from the stepped reduced neck of the barrel. The medicine container also comprises an elastic seal, which is configured to seal the outlet end and comprises a flange portion, which is adjacent to the outlet end in the longitudinal or axial direction. The elastic seal may comprise an elastic plug configured to be inserted into the outlet end. In other examples, the elastic seal comprises an elastic disc-shaped diaphragm, which is configured to abut the distal end face of the barrel without entering the outlet hole of the barrel.

[0040] Medicament container also comprises closure cap as above.Here, the retainer part of closure cap engages with elastic seal.The buckle feature of the fastening part of closure cap releasably engages with the radial widening edge of outlet end, so that elastic seal is kept and / or fixed on the outlet end or in the proper position on the outlet end.Typically, retainer part, for example facing the proximal abutment surface, for example consistent with the cup-shaped receiving portion formed by the sidewall of cover and cap body, with the outer surface close axial abutment or engagement facing the distal end of elastic seal.The buckle feature just engages with the proximal end of the radial widening edge of cylindrical shell, and elastic seal is kept and fixed on the proper position of outlet end.

[0041] According to another example, a medicament such as a parenteral drug is arranged in the barrel. The medicament may include a liquid injectable medicament. In other examples, the medicament is provided in the form of a dry powder in the barrel. Here, the dry powder must be mixed with a solvent or diluent to prepare a liquid medicament. The disassembly of the closure cap can be particularly useful for filling the interior of the barrel with a suitable diluent or solvent.

[0042] According to another example, the barrel includes at least one through opening in a region deviating from the outlet end. Here, the barrel is configured as a leak test barrel. The barrel may include a leak test barrel. The size of the through opening may be 1 μm to 100 μm. In other examples, the through opening has a lateral dimension or diameter between 2 μm and 50 μm. In a further example, at least one through opening includes a lateral dimension or diameter of about 5 μm to 15 μm.

[0043] The at least one through opening can be a laser drilled through opening in the glassy material of the barrel. Typically, the through opening extends through the sidewall or bottom and / or shoulder of the barrel. Here, the barrel can be made of a glassy material. The barrel can include a glass barrel.

[0044] The removable arrangement and / or fixing of the elastomeric seal provided by the closure cap to the outlet end of the barrel is particularly useful for carrying out a series of leak tests with the same specially prepared barrel. Here, a number of seals may have to be properly assembled and fixed one after another to the outlet end of the same barrel. Each barrel seal combination is subjected to a leak test, such as a helium leak test. In order to replace such elastomeric seals, a removable closure cap has particular value and benefit.

[0045] In general, the scope of the present disclosure is defined by the content of the claims. The injection device is not limited to a specific embodiment or example, but includes any combination of elements of different embodiments or examples. In this regard, the present disclosure covers any combination of claims and any technically feasible combination of features disclosed in combination with different examples or embodiments.

[0046] In the present context, the term "distal" or "distal end" relates to the end of the medicament container facing the outlet end or comprising the outlet end. The term "proximal" or "proximal end" relates to the opposite end of the container, which is farthest from the outlet end.

[0047] As used herein, the term "drug" or "pharmaceutical agent" refers to a pharmaceutical preparation containing at least one pharmaceutically active compound, wherein, in one embodiment, the pharmaceutically active compound has a molecular weight of up to 1500 Da and / or is a peptide, protein, polysaccharide, vaccine, DNA, RNA, enzyme, antibody or antibody fragment, hormone or oligonucleotide, or a mixture of the above pharmaceutically active compounds,

[0048] Wherein, in another embodiment, the pharmaceutically active compound can be used to treat and / or prevent diabetes or complications associated with diabetes (such as diabetic retinopathy), thromboembolic disease (such as deep vein or pulmonary thromboembolism), acute coronary syndrome (ACS), angina pectoris, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and / or rheumatoid arthritis,

[0049] Wherein, in another embodiment, the pharmaceutically active compound comprises at least one peptide for treating and / or preventing diabetes or complications associated with diabetes (such as diabetic retinopathy),

[0050] Among them, in other embodiments, the pharmaceutically active compound includes at least one human insulin or human insulin analog or derivative, glucagon-like peptide (GLP-1) or its analog or derivative, or exendin-3 or exendin-4, or an analog or derivative of exendin-3 or exendin-4.

[0051] Insulin analogs are, for example, Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin in which the proline at position B28 is replaced by Asp, Lys, Leu, Val or Ala, and in which position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.

[0052] Insulin derivatives are, for example, B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoylLysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB2 9LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-γ-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-γ-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.

[0053] Exendin-4 refers, for example, to Exendin-4 (1-39), a peptide having the following sequence: H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.

[0054] The exendin-4 derivative is, for example, selected from the following list of compounds:

[0055] H-(Lys)4-des Pro36,des Pro37 exendin-4(1-39)-NH2,

[0056] H-(Lys)5-des Pro36,des Pro37 exendin-4(1-39)-NH2,

[0057] des Pro36 exendin-4 (1-39),

[0058] des Pro36[Asp28] exendin-4(1-39),

[0059] des Pro36[IsoAsp28] exendin-4(1-39),

[0060] des Pro36[Met(O)14,Asp28]exendin-4(1-39),

[0061] des Pro36[Met(O)14,IsoAsp28]exendin-4(1-39),

[0062] des Pro36[Trp(O2)25,Asp28]exendin-4(1-39),

[0063] des Pro36[Trp(O2)25,IsoAsp28]exendin-4(1-39),

[0064] des Pro36[Met(O)14Trp(O2)25,Asp28]exendin-4(1-39),

[0065] des Pro36[Met(O)14Trp(O2)25,IsoAsp28]exendin-4(1-39); or

[0066] des Pro36[Asp28] exendin-4(1-39),

[0067] des Pro36[IsoAsp28] exendin-4(1-39),

[0068] des Pro36[Met(O)14,Asp28]exendin-4(1-39),

[0069] des Pro36[Met(O)14,IsoAsp28]exendin-4(1-39),

[0070] des Pro36[Trp(O2)25,Asp28]exendin-4(1-39),

[0071] des Pro36[Trp(O2)25,IsoAsp28]exendin-4(1-39),

[0072] des Pro36[Met(O)14Trp(O2)25,Asp28]exendin-4(1-39),

[0073] des Pro36[Met(O)14Trp(O2)25,IsoAsp28]exendin-4(1-39),

[0074] Among them, the group -Lys6-NH2 can bind to the C-terminus of the exendin-4 derivative;

[0075] or an exendin-4 derivative having the following sequence:

[0076] des Pro36 exendin-4(1-39)-Lys6-NH2(AVE0010),

[0077] H-(Lys)6-des Pro36[Asp28] exendin-4(1-39)-Lys6-NH2,

[0078] des Asp28 Pro36,Pro37,Pro38 Exendin-4(1-39)-NH2,

[0079] H-(Lys)6-des Pro36,Pro38[Asp28]exendin-4(1-39)-NH2,

[0080] H-Asn-(Glu)5des Pro36,Pro37,Pro38[Asp28] exendin-4(1-39)-NH2、desPro36,Pro37,Pro38[Asp28] exendin-4(1-39)-(Lys)6-NH2、H-(Lys)6-des Pro36,Pro37,Pro38[Asp28] exendin-4(1-39)-(Lys)6-NH2、H-Asn-(Glu)5-des Pro36,Pro37,Pro38[Asp28] exendin-4(1-39)-(Lys)6-NH2、H-(Lys)6-des Pro36[Trp(O2)25,Asp28] exendin-4(1-39)-Lys6-NH2、H-des Asp28 Pro36, Pro37, Pro38 [Trp (O2) 25] exendin-4 (1-39) -NH2, H-(Lys) 6-des Pro36, Pro37, Pro38 [Trp (O2) 25, Asp28] exendin-4 (1-39) -NH2, H-Asn-(Glu) 5-des Pro36, Pro37, Pro38 [Trp (O2) 25, Asp28] exendin-4 (1-39) -NH2, des Pro36, Pro37, Pro38 [Trp (O2) 25, Asp28] exendin-4 (1-39) -(Lys) 6-NH2, H-(Lys) 6-des Pro36, Pro37, Pro38 [Trp (O2) 25, Asp28] exendin-4 (1-39) - (Lys) 6-NH2, H-Asn-(Glu) 5-des Pro36, Pro37, Pro38 [Trp (O2) 25, Asp28] exendin-4 (1-39) - (Lys) 6-NH2, H-(Lys) 6-des Pro36 [Met (O) 14, Asp28] exendin-4 (1-39) - Lys 6-NH2, des Met (O) 14Asp28 Pro36, Pro37, Pro38 exendin-4(1-39)-NH2, H-(Lys)6-desPro36, Pro37, Pro38[Met(O)14, Asp28] exendin-4(1-39)-NH2, H-Asn-(Glu)5-des Pro36, Pro37, Pro38[Met(O)14, Asp28] exendin-4(1-39)-NH2, des Pro36, Pro37, Pro38[Met(O)14,Asp28] exendin-4(1-39)-(Lys)6-NH2, H-(Lys)6-des Pro36,Pro37,Pro38[Met(O)14,Asp28] exendin-4(1-39)-(Lys)6-NH2, H-Asn-(Glu)5des Pro36,Pro37,Pro38[Met(O)14,Asp28] exendin-4(1-39)-(Lys)6-NH2, H-Lys6-des Pro36[Met(O)14,Trp(O2)25,Asp28] exendin-4(1-39)-Lys6-NH2, H-des Asp28 Pro36, Pro37, Pro38 [Met (O) 14, Trp (O2) 25] exendin-4 (1-39) -NH2, H-(Lys) 6-des Pro36, Pro37, Pro38 [Met (O) 14, Asp28] exendin-4 (1-39) -NH2, H-Asn-(Glu) 5-des Pro36, Pro37, Pro38 [Met (O) 14, Trp (O2) 25, Asp28] exendin-4 (1-39) -NH2,

[0081] des Pro36, Pro37, Pro38[Met(O)14, Trp(O2)25, Asp28] exendin-4(1-39)-(Lys)6-NH2, H-(Lys)6-des Pro36, Pro37, Pro38[Met(O)14, Trp(O2)25, Asp28] exendin-4(S1-39)-(Lys)6-NH2, H-Asn-(Glu)5-des Pro36, Pro37, Pro38[Met(O)14, Trp(O2)25, Asp28] exendin-4(1-39)-(Lys)6-NH2;

[0082] Or a pharmaceutically acceptable salt or solvate of any of the above exendin-4 derivatives.

[0083] Hormones are, for example, pituitary hormones or hypothalamic hormones or regulatory active peptides as listed in Chapter 50 of the Rote Liste, 2008 edition, and their antagonists, such as gonadotropins (Follitropin, Luteinizing Hormone, Choriongonadotropin, Gametogenic Hormone), somatropine (Somatropin), desmopressin, terlipressin, gonadorelin, triptorelin, leuprorelin, buserelin, nafarelin, goserelin.

[0084] The polysaccharide is, for example, a glycosaminoglycan, hyaluronic acid, heparin, a low molecular weight heparin or an ultra-low molecular weight heparin or a derivative thereof, or a sulfated form (e.g., a polysulfated form) of the polysaccharide, and / or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a polysulfated low molecular weight heparin is enoxaparin sodium.

[0085] Antibodies are globular plasma proteins (about 150 kDa), also called immunoglobulins, that share a basic structure. They are glycoproteins because of the addition of sugar chains to amino acid residues. The basic functional unit of each antibody is the immunoglobulin (Ig) monomer (containing only one Ig unit); secreted antibodies can also be dimers with two Ig units (such as IgA), tetramers with four Ig units (such as bony fish IgM), or pentamers with five Ig units (such as mammalian IgM).

[0086] The Ig monomer is a "Y" shaped molecule composed of four polypeptide chains; two identical heavy chains and two identical light chains are connected by disulfide bonds between cysteine ​​residues. Each heavy chain is about 440 amino acids long; each light chain is about 220 amino acids long. The heavy and light chains each contain intrachain disulfide bonds that stabilize their folding. Each chain is composed of domains called Ig domains. These domains contain about 70-110 amino acids and are divided into different categories (such as variable regions or V regions and constant regions or C regions) based on their size and function. These domains have a characteristic immunoglobulin fold in which two beta folds are "sandwiched" together by interactions between conserved cysteines and other charged amino acids.

[0087] There are five types of mammalian Ig heavy chains, denoted α, δ, ε, γ, and μ. The type of heavy chain present defines the antibody's isotype; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively.

[0088] The different heavy chains vary in size and composition; α and γ contain approximately 450 amino acids, δ contains approximately 500 amino acids, and μ and ε contain approximately 550 amino acids. Each heavy chain has a constant region (CH ) and variable region (V H ) two regions. In one species, the constant region is essentially the same in all antibodies of the same isotype, but different in antibodies of different isotypes. Heavy chains γ, α, and δ have a constant region consisting of three tandem Ig domains, and a hinge region for increased flexibility; heavy chains μ and ε have a constant region consisting of four immunoglobulin domains. The variable region of the heavy chain is different in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone. The variable region of each heavy chain is about 110 amino acids long and consists of a single Ig domain.

[0089] In mammals, there are two types of immunoglobulin light chains, denoted by λ and κ. A light chain has two consecutive domains: a constant domain (CL) and a variable domain (VL). The approximate length of a light chain is 211 to 217 amino acids. Each antibody contains two light chains that are always identical; in mammals, only one type of light chain, κ or λ, exists for each antibody.

[0090] Although the general structure of all antibodies is very similar, the unique properties of a given antibody are determined by the variable (V) regions as detailed above. More specifically, the variable loops (three per light chain (VL) and three on the heavy chain (VH)) are responsible for binding to the antigen, i.e., for its antigen specificity. These loops are called complementarity determining regions (CDRs). Because multiple CDRs from the VH domain and the VL domain make up the antigen binding site, it is the combination of the heavy and light chains (rather than each alone) that determines the final antigen specific combination.

[0091] "Antibody fragments" include at least one antigen-binding fragment as defined above, and exhibit essentially the same function and specificity as the complete antibody from which they are derived. Limited proteolysis with papain cleaves the Ig prototype into three fragments. Two identical amino-terminal fragments are antigen-binding fragments (Fab), each containing a complete L chain and about half of an H chain. The third fragment is a crystallizable fragment (Fc), which is similar in size but contains half of the carboxyl termini of the two heavy chains and their interchain disulfide bonds. Fc contains carbohydrates, complement binding sites, and FcR binding sites. Limited pepsin digestion produces a single F(ab')2 fragment, which contains both the Fab segment and the hinge region, including the HH interchain disulfide bonds. F(ab')2 is divalent for antigen binding. The disulfide bonds of F(ab')2 can be cleaved to obtain Fab'. In addition, the variable regions of the heavy and light chains can be fused together to form a single-chain variable fragment (scFv).

[0092] Pharmaceutically acceptable salts are, for example, acid addition salts and basic salts. Acid addition salts are, for example, HCl or HBr salts. Basic salts are, for example, salts with cations selected from alkali or alkaline earth metals, for example, Na+, or K+, or Ca2+, or ammonium ions N+(R1)(R2)(R3)(R4), wherein R1 to R4 represent, independently of one another, hydrogen, optionally substituted C1-C6-alkyl groups, optionally substituted C2-C6-alkenyl groups, optionally substituted C6-C10-aryl groups, or optionally substituted C6-C10-heteroaryl groups. Other examples of pharmaceutically acceptable salts are described in the following documents: "Remington's Pharmaceutical Sciences" 17th edition Alfonso R. Gennaro (ed.), Mark Publishing Company, Easton, Pa., USA, 1985 and Encyclopedia of Pharmaceutical Technology.

[0093] Pharmaceutically acceptable solvates are, for example, hydrates.

[0094] It is also clear to those skilled in the art that various modifications and variations may be made to the present disclosure without departing from the scope of the present disclosure. In addition, it should be noted that any reference numerals used in the appended claims should not be construed as limiting the scope of the present disclosure. BRIEF DESCRIPTION OF THE DRAWINGS

[0095] In the following, a number of examples of injection devices comprising a fill level indicator will be described in more detail with reference to the accompanying drawings, in which:

[0096] FIG. 1 is a schematic perspective view of a pharmaceutical container implemented as a leak test container,

[0097] FIG. 2 is an isolated perspective view of the closure cap,

[0098] FIG3 is a cross-sectional view of the closure cap of FIG2 ,

[0099] Figure 4 is a longitudinal cut through the closure cap when assembled to the outlet end of the barrel,

[0100] FIG5 is a partial view of the lower gripping surface of the outer flange portion of the closure cap viewed from below,

[0101] FIG6 is a cross-section of another example of a closure cap fitted with a tamper-evident seal, and

[0102] FIG. 7 schematically shows the structure of an example of a tamper-evident seal. DETAILED DESCRIPTION

[0103] In FIG. 1 , an example of a pharmaceutical container 1 is shown. The pharmaceutical container can be implemented as a bottle or a vial. The pharmaceutical container 1 comprises a barrel 2, which comprises a substantially cylindrical side wall 3. The side wall 3 is limited towards the proximal direction by a bottom 5. The bottom 5 is substantially circular. Opposite to the bottom 5, the side wall 3 extends into a radially narrowing shoulder 8. The shoulder 8 extends in the longitudinal and distal directions into a stepped neck 6. The neck 6 has a relatively constant diameter when viewed in the longitudinal or distal direction.

[0104] At the extreme end, the barrel 2 comprises an outlet end 7. At the outlet end, the barrel 2 comprises a radially widened rim 11. As shown in Fig. 4, the inner surface 18 in the region of the neck 6 extends unaltered towards the distal end face 12 of the barrel 2. The radially widened outer rim 11 is only provided on the outer surface of the barrel 2. From a longitudinal view, the diameter or cross-section of the inner surface 12 of the head 10 and the proximally adjacently located neck 6 is relatively constant.

[0105] As shown in FIG. 4 , this tubular shape of the inner surface 18 is particularly configured to receive a corresponding tubular insertion area 86 of an elastomeric seal 80. The elastomeric seal 80 typically includes a plug 82 or plug body made of an elastomeric material (e.g., natural or synthetic rubber) that can be inserted into the outlet end 7 of the barrel 2. The seal 80 and the plug 82 are used to seal the outlet end 7 of the barrel in a liquid-tight and / or air-tight manner. The seal 80 includes a flange portion 94 extending radially outward. The flange portion 94 includes a proximal surface 92 that abuts against a correspondingly shaped distal end face 12 of the head 10 of the barrel 2.

[0106] The radial extension of the flange portion 94 is substantially equal to the radial extension of the distal face 12. Within certain limits, the entire distal face 12 of the barrel 2 can be covered and can be sealingly engaged with the proximal surface 92 of the flange portion 94. In addition, the outer surface 87 of the insertion area 86 is sealingly engaged with the inner surface 18 of the combined head 10 and neck 6. Here too, a liquid-tight and / or gas-tight seal can be obtained between the seal 80 and the outlet end 7 of the barrel 2.

[0107] As further shown in FIG. 4 , the radially outer surface 13 of the head 10 of the cartridge 2 is substantially flush in the longitudinal or axial direction with the radially outwardly facing outer surface 83 of the seal 80 or plug 82 .

[0108] 4, the insertion region 87 of the plug 82 includes a centrally located hollow region 90. In other words, the radially central portion of the upper or distal end section of the seal 80 includes a reduced longitudinal thickness compared to the radially outwardly located portions of the insertion region 86. In this regard, the insertion region 86 includes a tubular-like sidewall 88 having a hollow longitudinal interior 90. In this manner, and while being accessible from the outside, the radially central region of the seal 80 can be easily penetrated by a puncture assembly, such as a cannula or an injection needle.

[0109] The seal 80 or plug 82 is typically made of chlorobutyl rubber or bromobutyl rubber or a combination thereof.

[0110] In order to provide a removable seal to the dosage container 1, the dosage container 1 also includes a removable closure cap 20, as shown in more detail in Figures 2 and 3. The cap 20 includes a cap body 22. The cap body 22 includes a disc-like retainer portion 24 that forms or contributes to the upper cover portion 60. The retainer portion 24 includes a proximally facing abutment surface 25, which is in surface abutment or surface pressure with the upward or distally facing outer surface 85 of the seal 80 in the intended assembly configuration shown in Figure 4.

[0111] Cap 22 also includes a fastening portion 26 extending away from the lower side or proximal side of retainer portion 24. Fastening portion 26 includes a fastener 28 that can be elastic and radially deformed. Fastener 28 includes snap-on features 30. The snap-on features 30 are configured to releasably engage with the radially widened edge 11 of outlet port 7, as shown in Figure 4. In the example shown at present, fastening portion 26 and fastener 28 are integrated into tubular sidewall 40. Sidewall 40 is integrally formed with the retainer portion 24 of cap 22. In addition, retainer portion 24 and cover 60 and sidewall 40 can be integrally formed. Cap 22 can include or can be composed of an integral, for example injection-molded plastic component that is easy to manufacture and assemble. In addition, injection-molded cap can be manufactured in large quantities with medium or low cost.

[0112] 3, the snap feature 30 is located at a longitudinal distance D from the retainer portion 24. Specifically, the snap feature 30 is spaced or spaced apart from the proximally facing abutment surface 25 of the retainer portion 24 or cover portion 60 by a longitudinal or axial distance D. The longitudinal or axial distance D is sized such that when the seal 80 is properly disposed on or in the outlet end 7, the seal remains free of slack relative to the outlet end 7. In some examples, the longitudinal distance D is slightly less than the sum of the longitudinal extension of the flange portion 94 and the longitudinal extension of the radially widened rim 11.

[0113] In this way, establishing a snap-fit ​​connection between the snap feature 30 at the proximal end of the radially widened rim 11 and the recessed portion 14 is possible only with at least a slight axial or longitudinal compression of the seal 80. In this way, a well-defined surface pressure can be obtained between the proximal surface 92 of the seal 80 and the distal face 12 of the barrel 2.

[0114] The snap feature 30 comprises a projection 34 extending radially inwards. The projection 34 protrudes radially inwards from the inner surface 32 of the sidewall 40. The projection 34 extending radially inwards is positioned at or near the near end or free end 27 of the fastening portion 26, fastener 28 and / or the sidewall 40. As further shown in Figure 3, the projection 34 comprises a chamfered edge 36 facing the distal side and an introduction ramp 38 facing the proximal side. The introduction ramp 38 is also a chamfered edge. The inclination of the chamfered edge 36 facing the distal side is slightly steeper than the inclination of the introduction ramp 38. The introduction ramp 38 is used to cause the radial widening or radially outward deformation of the snap feature 30 in the process of pushing the closure cap 20 onto the seal 80 assembled on the outlet port 7 from above. Here, in the process of assembling the closure cap 20 to the barrel 2 and the seal 80, the introduction ramp 38 can engage the radially outwardly positioned edge of the outer surface 85 of the seal.

[0115] The chamfered edge 36 is configured to cause radial widening or radial outward deformation of the snap feature 30 when the closure cap 20 is removed from the barrel 2, thereby causing radial widening or radial outward deformation of the fastening portion 26, the fastener 28 and / or the side wall 40. Here, as shown in Figure 4, the chamfered edge 36 engages with the proximal edge of the radially widened rim 11. When the closure cap 20 is pulled down from the outlet end in the distal direction relative to the barrel 2, as the radially inwardly extending protrusion 34 slides along the outer surface 13 of the radially widened rim 11, the chamfered edge 36 causes a corresponding radial outward deformation.

[0116] The snap feature 30 can include a plurality of radially inwardly extending protrusions 34 distributed on the inwardly facing inner surface 32 of the sidewall 40. In some examples, the snap feature 30 includes a peripheral rim 44 protruding radially inwardly from the sidewall 40.

[0117] As further shown in Fig. 3 and Fig. 5, cover 60 forms cup-shaped receiving portion 41 with sidewall 40.In addition, cover 60 comprises outer flange 50 extending radially outwards, which extends radially outwards from the outer surface 42 of sidewall 40. Outer flange or outer flange portion 50 can also be formed as one piece with retainer portion 24 and sidewall 40. Outer flange portion 50 is also integrated into cap body 22. Outer flange portion 50 comprises gripping surface 51 protruding radially outwards from the outer surface 42 of sidewall 40. Gripping surface 51 faces sidewall 42. Outer flange portion 50 is the radially outward extension of retainer portion 24. The upper surface of flange portion 50 or the surface facing the distal side is flush with the outer surface 62 of cover 60 radially. The gripping surface positioned relatively faces the proximal direction.As shown in Figure 5, gripping surface 51 is provided with outer edge 52. The outer rim 52 protrudes in the proximal direction and thus protrudes towards the outer surface 42 of the side wall 40 on the radial outer edge of the flange portion 50. The outer rim 52 is used to provide a non-slip grip of the lower gripping surface 51 when the user wants to lift the closure cap 20 during the process of removing the closure cap from the outlet end 7 of the barrel 2.

[0118] As shown in FIG5 , a plurality of spokes or struts 56 are provided extending radially inwardly from the outer edge 52. These struts 56 also protrude longitudinally from the lower gripping surface 51. The struts 56 may be arranged equidistantly along the outer circumference of the outer surface 42. The struts 56 are configured to provide mechanical stability and increase the rigidity of the flange portion 50.

[0119] As further shown in FIG6 , the closure cap 20 is provided with a tamper-evident seal 100. The tamper-evident seal 100 comprises a frangible region 102. The frangible region may in turn comprise at least a first frangible section 104 and a second frangible section 106. In the schematic diagram of the tamper-evident seal 100 as shown in FIG7 , the frangible region further comprises a third frangible section 108. The frangible sections 104, 106, 108 are interconnected by a frangible connector 112. In the example of FIG7 , each frangible section is also frangibly connected to the side wall 40 of the closure cap 20. For this purpose, an additional frangible connector 114 is provided.

[0120] As further shown in Fig. 6, the frangible area is located at the free end 27 of the side wall and may protrude in the proximal direction from the side wall 40. The inner diameter of the frangible area 102 may be adapted to receive the radially stepped neck 6 of the barrel 2. However, the inner diameter of the frangible area 102 is smaller than the outer diameter of the radially widened rim 11. Therefore, in order to remove the closure cap from the outlet end 7, at least one of the frangible connections 112, 114 must be broken to allow the disintegrated frangible area to slide over or pass the radially widened rim 11.

[0121] The tamper-evident seal may be formed integrally with the closure cap. In some examples, it may be welded to the closure cap or connected to the closure cap by an adhesive.

[0122] When the medicine container 1 contains a medicament in liquid or powder form, it is particularly beneficial to use a tamper-evident seal 100. For other examples and as shown in Figure 1, this tamper-evident seal 100 may not be needed. In Figure 1, the barrel 2 of the medicine container 1 includes at least one or more through openings 9 in a region away from or deviating from the outlet end 7. The through opening 9 can be a laser drilled hole of a predetermined size or a laser-generated hole in the bottom 5 of the sidewall 3, shoulder 8, neck 6 or barrel 2. In the case where the outlet end 7 is sealed by an elastic seal 80, this at least one dedicated and clearly defined through opening is required to carry out a gas leak test of the medicine container. When using the same barrel 2, a detachable and reattachable closure cap 20 enables multiple seals 80 to be replaced one by one, so as to carry out a leak test. The detachable closure cap 20 is conducive to avoiding the rupture or damage of the barrel when the closure cap is disassembled to replace the elastic seal.

[0123] Reference numerals list

[0124] 1 Medicine container

[0125] 2 Cylinder

[0126] 3 Sidewall

[0127] 4 Internal volume

[0128] 5 Bottom

[0129] 6 Neck

[0130] 7 Exit

[0131] 8 Shoulders

[0132] 9 Through opening

[0133] 10 Head

[0134] 11 Edge

[0135] 12 Distal surface

[0136] 13 External surface

[0137] 14 Depression

[0138] 16 Contact surface / adjacent surface

[0139] 18 Inner surface

[0140] 20 Closing cap

[0141] 22 cap body

[0142] 24 Retainer part

[0143] 25 Adjacent surfaces

[0144] 26 Fastening part

[0145] 27 Free end

[0146] 28 Fasteners

[0147] 30 Snap-on features

[0148] 32 Inner surface

[0149] 34 protrusion

[0150] 36 Bevel Edge

[0151] 38 Lead-in bevel

[0152] 40 Sidewall

[0153] 41 Receiving Department

[0154] 42 External surface

[0155] 44 Edge

[0156] 50 Outer flange part

[0157] 51 Grip Surface

[0158] 52 outer edge

[0159] 56 Pillar

[0160] 60 cover

[0161] 62 External surface

[0162] 64 Base Area

[0163] 65 Base side

[0164] 66 Pedestal Top

[0165] 68 Plinth Area

[0166] 69 Base side

[0167] 70 Base top

[0168] 80 Seals

[0169] 82 plug

[0170] 83 External surface

[0171] 84 Plug body

[0172] 85 External surface

[0173] 86 Insertion area

[0174] 87 External surface

[0175] 88 Sidewall

[0176] 90 Hollow Area

[0177] 92 proximal surface

[0178] 94 flange part

[0179] 100 Tamper-evident seals

[0180] 102 Fragile Zone

[0181] 104 Sections

[0182] 106 Sections

[0183] 108 Sections

[0184] 110 Perforation connection

[0185] 112 Breakaway connector

[0186] 114 Breakaway connector

Claims

1. A closure cap for sealing an outlet end (7) of a barrel (2) of a medicine container (1), the outlet end (7) having a radially widened edge (11), and the outlet end (7) can be sealed by an elastic seal (80), wherein the elastic seal (80) comprises a flange portion (94) configured to abut against the outlet end (7) in a longitudinal direction, the closure cap (20) comprising: a cap body (22) comprising a cover portion (60) and a side wall (40), said cover portion (60) and said side wall (40) forming a cup-shaped receiving portion (41) configured to receive the radially widened rim (11) of said outlet end (7) and the flange portion (94) of said elastic seal (80), - wherein the cover (60) is configured to engage with the elastic seal (80), - wherein the side wall (40) comprises an elastically and radially deformable fastener (28) comprising a snap feature (30) configured to releasably engage with a radially widened rim (11) of the outlet end (7), and - wherein the longitudinal distance (D) between the cover portion (60) and the snap feature (30) is dimensioned to receive the radially widened rim (11) of the outlet end (7) and the flange portion (94) of the resilient seal (80) between the cover portion (60) and the snap feature (30), and - wherein the longitudinal thickness of the cover portion (60) at the radial center of the cover portion (60) is greater than the longitudinal thickness of the cover portion (60) at a radial distance from the radial center of the cover portion.

2. The closure cap according to claim 1, wherein the elastically and radially deformable fastener (28) is capable of detaching and releasing the snap feature (30) from the radially widened rim (11) when an upward pulling force above a predetermined threshold is applied.

3. A closure cap according to claim 1 or 2, wherein the longitudinal distance (D) between the cover portion (60) and the snap feature (30) is less than or equal to the sum of the longitudinal extension of the radially widened edge (11) of the outlet end (7) and the longitudinal thickness of the flange portion (94) of the elastic seal (80).

4. A closure cap according to claim 3, wherein the longitudinal distance (D) between the cover portion (60) and the snap feature (30) is smaller than the sum of the longitudinal extension of the radially widened rim (11) and the longitudinal thickness of the flange portion (94) of the elastic seal (80), and wherein when the snap feature (30) and the radially widened rim (11) are snap-fitted into engagement, the elastic seal (80) obtains longitudinal compression.

5. The closure cap according to claim 1 or 2, wherein the snap feature (30) comprises a protrusion (34) protruding from the inner surface (32) of the side wall (40).

6. The closure cap according to claim 1 or 2, wherein the side wall (40) is tubular, and wherein the snap feature (30) comprises a radially inwardly projecting rim (44).

7. A closure cap according to claim 1 or 2, wherein when assembled, the cover portion (60) comprises an abutment surface (25) facing the outer surface (85) of the elastic seal (80) and directly abutting the outer surface (85) of the elastic seal (80).

8. The closure cap according to claim 1 or 2, wherein the snap feature (30) is located at or near a free end (27) of the side wall (40) facing away from the cover portion (60).

9. The closure cap according to claim 1 or 2, wherein the snap feature (30) comprises a lead-in ramp (38) for engaging with at least one of a flange portion (94) of the resilient seal (80) and a radially widened rim (11) of the outlet end (7).

10. The closure cap according to claim 1 or 2, wherein the cover portion (60) and the side wall (40) are integrally formed, and wherein the cap body (22) is made of a polymeric material.

11. The closure cap according to claim 1 or 2, wherein the cover portion (60) and the side wall (40) are integrally formed, and wherein the cap body (22) is made of a plastic material.

12. The closure cap according to claim 1 or 2, further comprising an outer flange portion (50) protruding radially outwardly from at least one of the cover portion (60) and the side wall (40).

13. The closure cap according to claim 12, wherein the outer flange portion (50) comprises a radially outwardly extending extension of the cover portion (60).

14. Closure cap according to claim 12, wherein the outer flange portion (50) comprises a lower gripping surface (51) facing the side wall (40).

15. A closure cap according to claim 14, wherein the outer flange portion (50) includes an outer rim (52) protruding longitudinally from the lower gripping surface (51), and wherein the outer flange portion (50) includes a plurality of radially extending struts (56) extending from the side wall (40) to the outer rim (52).

16. The closure cap according to claim 1 or 2, wherein the side wall (40) comprises a tamper-evident seal (100), the tamper-evident seal (100) comprising a frangible zone (102), the frangible zone (102) comprising at least a first frangible section (104) and a second frangible section (106), wherein the first frangible section (104) and the second frangible section (106) are connected to each other by a frangible connector (112).

17. A medicine container (1), comprising: - a cylinder (2) comprising an outlet end (7), wherein said outlet end (7) has a radially widened rim (11), - an elastic seal (80) configured to seal the outlet end (7) and comprising a flange portion (94) to abut against the outlet end (7) in a longitudinal direction, - A closure cap (20) according to any of the preceding claims, wherein a cover portion (60) of the closure cap (20) engages with the resilient seal (80), and wherein a snap feature (30) of the side wall (40) of the closure cap (20) releasably engages with a radially widened rim (11) of the outlet end (7) to hold the resilient seal (80) in place on the outlet end (7).

18. The medicine container according to claim 17, wherein the cylinder (2) contains medicine.

19. A medicament container according to claim 17, wherein the barrel (2) comprises at least one through-opening (9) in a region deviating from the outlet end (7), and wherein the barrel (2) is configured as a leak test barrel.